Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient
AssigneeUniversity of Iowa Research Foundation
InventorsKevin P. Campbell, Yvonne M. Kobayashi, Robert W. Crawford
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions and methods for treating or preventing muscle diseases or the symptoms thereof. The compositions typically include and the methods typically utilize phosphodiesterase type 5A inhibitors.
Claims23
A method for treating muscular dystrophy in a patient, the method comprising administering to the patient an effective amount of sildenafil, a sildenafil analog, a sildenafil derivative, or a pharmaceutical salt thereof having phosphodiesterase type 5A inhibitory activity.
A method for reducing fatigue in a patient having as muscle disease, the method comprising administering an effective amount of a phosphodiesterase type 5A inhibitor or a pharmaceutical salt thereof to the patient.
-21. (canceled)
-27. (canceled)
A method for reducing the likelihood of edema occurring after exercise in a patient having a muscle disease, the method comprising administering to the patient an effective amount of sildenafil, a sildenafil analog, a sildenafil derivative, or a pharmaceutical salt thereof having phosphodiesterase type 5A inhibitory activity prior to exercise.
-34. (canceled)
Dependencies are inferred from the claim text.